Compare CRMT & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRMT | BNR |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.2M | 216.9M |
| IPO Year | N/A | 2020 |
| Metric | CRMT | BNR |
|---|---|---|
| Price | $21.38 | $29.18 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $37.00 | N/A |
| AVG Volume (30 Days) | ★ 89.3K | 23.5K |
| Earning Date | 03-05-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,381,482,000.00 | $75,749,382.00 |
| Revenue This Year | $2.41 | $136.32 |
| Revenue Next Year | $4.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.01 | ★ 5.56 |
| 52 Week Low | $17.78 | $2.18 |
| 52 Week High | $62.72 | $41.72 |
| Indicator | CRMT | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 30.00 | 50.03 |
| Support Level | $20.93 | $28.28 |
| Resistance Level | $26.75 | $34.26 |
| Average True Range (ATR) | 1.43 | 3.24 |
| MACD | -0.58 | -1.11 |
| Stochastic Oscillator | 5.45 | 15.56 |
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.